Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

RedHill Biopharma (RDHL) Operating Leases (2019 - 2025)

RedHill Biopharma has reported Operating Leases over the past 7 years, most recently at $900000.0 for Q4 2025.

  • Quarterly Operating Leases rose 29900.0% to $900000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $900000.0 through Dec 2025, up 29900.0% year-over-year, with the annual reading at $900000.0 for FY2025, 29900.0% up from the prior year.
  • Operating Leases was $900000.0 for Q4 2025 at RedHill Biopharma, up from $3000.0 in the prior quarter.
  • Over five years, Operating Leases peaked at $6.4 million in Q4 2022 and troughed at $3000.0 in Q4 2024.
  • The 5-year median for Operating Leases is $900000.0 (2025), against an average of $2.1 million.
  • Year-over-year, Operating Leases plummeted 99.34% in 2024 and then surged 29900.0% in 2025.
  • A 5-year view of Operating Leases shows it stood at $2.6 million in 2021, then skyrocketed by 150.31% to $6.4 million in 2022, then tumbled by 92.94% to $455000.0 in 2023, then plummeted by 99.34% to $3000.0 in 2024, then surged by 29900.0% to $900000.0 in 2025.
  • Per Business Quant, the three most recent readings for RDHL's Operating Leases are $900000.0 (Q4 2025), $3000.0 (Q4 2024), and $455000.0 (Q4 2023).